CSRxP Statement On House & Senate Committee Hearings On Skyrocketing Drug Prices

Jan 29, 2019

For Immediate Release:
Contact: Lauren Blair
(201) 213-5004
[email protected]

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) executive director, Lauren Aronson, today released the following statement after the U.S. House Oversight and Reform and U.S. Senate Finance Committees held their first hearings on drug pricing:

“We appreciate the commitment of Senate Finance Committee Chairman Grassley and Ranking Member Wyden and House Oversight and Reform Chairman Cummings and Ranking Member Jordan to tackle drug prices in the 116th Congress.  The fact that the first hearings held in these committees were about skyrocketing drug prices sent a clear message to Big Pharma that Congress is ready to hold them accountable for their price-gouging tactics.  As mothers of diabetic children testified today, this is a matter of life or death.  We look forward to working with lawmakers on both sides of the aisle in the coming months to enact bipartisan solutions that lower prices and protect patients.  As Congress continues efforts to advance bipartisan, market-based solutions, we hope drug manufacturers join this conversation – rather than standing on the sidelines – to make drugs more affordable for all Americans – especially those who need these live-saving medicines.”

To read CSRxP’s testimony submitted for the record to the House Oversight and Reform Committee, click HERE. To read CSRxP’s testimony submitted for the record to the Senate Finance Committee, click HERE.